Organon & Co (OGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Organon & Co (OGN) has a cash flow conversion efficiency ratio of 0.249x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($225.00 Million) by net assets ($903.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Organon & Co defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Organon & Co - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Organon & Co's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Organon & Co Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Organon & Co ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Stride Inc
NYSE:LRN
|
0.135x |
|
Shenzhen Hopewind Elec Co Ltd
SHG:603063
|
0.038x |
|
HARBOUR ENE.SP.ADR LS-50
F:PQQ2
|
N/A |
|
GEK TERNA Holdings Real Estate Construction S.A
AT:GEKTERNA
|
0.030x |
|
Korn Ferry
NYSE:KFY
|
0.116x |
|
Suzhou UIGreen Micro & Nano Technologies Co. Ltd. A
SHG:688661
|
0.002x |
|
INDIVIOR PLC DL 050
F:2IVB
|
N/A |
|
Amcor plc
F:485
|
0.043x |
Annual Cash Flow Conversion Efficiency for Organon & Co (2018–2025)
The table below shows the annual cash flow conversion efficiency of Organon & Co from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Organon & Co market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $752.00 Million | $700.00 Million | 0.931x | -53.21% |
| 2024-12-31 | $472.00 Million | $939.00 Million | 1.989x | +117.43% |
| 2023-12-31 | $-70.00 Million | $799.00 Million | -11.414x | -1086.66% |
| 2022-12-31 | $-892.00 Million | $858.00 Million | -0.962x | +40.99% |
| 2021-12-31 | $-1.51 Billion | $2.46 Billion | -1.630x | -508.87% |
| 2020-12-31 | $5.49 Billion | $2.19 Billion | 0.399x | +1.36% |
| 2019-12-31 | $7.04 Billion | $2.77 Billion | 0.393x | -32.28% |
| 2018-12-31 | $6.35 Billion | $3.69 Billion | 0.581x | -- |
About Organon & Co
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive… Read more